Pancreatic Cancer Research

ResearcherKumamoto Regional Medical CenterActive in the last 2 years

Masahiko Hirota

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7651-5375; OpenAlex author ID A5024376962. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. An 8-Year Survivor after Three-Time Hepatectomies for Metachronous Pancreatic Adenocarcinoma Liver Metastases. Co-author DOI 10.70352/scrj.cr.25-0242↗
  2. Combined Neutrophil-to-Lymphocyte Ratio Score Is Associated With Chemotherapeutic Response and Predicts Prognosis in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16955↗
  3. Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution. Last author DOI 10.1186/s12893-022-01825-3↗
  4. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Co-author DOI 10.1007/s00535-018-01535-9↗
  5. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  6. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000624↗
  7. Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer. Co-author DOI 10.1177/0148607114520992↗
  8. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Co-author DOI 10.1007/s00595-013-0708-0↗
  9. Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. Co-author DOI 10.1016/j.ejca.2014.01.011↗
  10. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Co-author DOI 10.1245/s10434-010-1384-6↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirohisa Okabe · 4 shared papers, 2019–2026 · strength 0.74
  2. Hiroki Sugita · 3 shared papers, 2022–2026 · strength 0.67
  3. Toshiro Masuda · 2 shared papers, 2024–2026 · strength 0.50
  4. Naoki Umezaki · 2 shared papers, 2019–2026 · strength 0.38
  5. Hidetoshi Nitta · 2 shared papers, 2016–2026 · strength 0.35
  6. Hideo Baba · 3 shared papers, 2015–2024 · strength 0.33
  7. Akira Chikamoto · 5 shared papers, 2014–2019 · strength 0.30
  8. Daisuke Hashimoto · 5 shared papers, 2014–2019 · strength 0.27
  9. Kota Arima · 3 shared papers, 2016–2019 · strength 0.21
  10. Shigeki Nakagawa · 3 shared papers, 2015–2019 · strength 0.21
  11. Hideo Baba · 1 shared paper, 2019 · strength 0.08
  12. Masafumi Inomata · 1 shared paper, 2019 · strength 0.08
  13. Yoshihiko Maehara · 1 shared paper, 2019 · strength 0.08
  14. Masayo Tsukamoto · 1 shared paper, 2019 · strength 0.08
  15. Yuki Kitano · 1 shared paper, 2019 · strength 0.08
  16. Katsunori Imai · 1 shared paper, 2019 · strength 0.08
  17. Takanobu Yamao · 1 shared paper, 2019 · strength 0.08
  18. Tatsunori Miyata · 1 shared paper, 2019 · strength 0.08
  19. Takatsugu Ishimoto · 1 shared paper, 2019 · strength 0.08
  20. Hiroshi Takamori · 2 shared papers, 2011–2015 · strength 0.08
  21. Hideo Baba · 2 shared papers, 2011–2014 · strength 0.07
  22. Takayoshi Kaida · 1 shared paper, 2016 · strength 0.05
  23. Hideo Baba · 1 shared paper, 2016 · strength 0.05
  24. Johanna Laukkarinen · 1 shared paper, 2014 · strength 0.05
  25. Yasuyuki Yamashita · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.